Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about mitochondrial_transfer: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| neuroprotection | mediates | phenotype | 0.95 |
| peripheral neuropathy | protects_against | unknown | 0.95 |
| brain injury | involved_in | unknown | 0.95 |
| neurodegeneration | involved_in | disease | 0.95 |
| blood-brain barrier integrity | associated_with | unknown | 0.95 |
| tumour_microenvironment | involved_in | unknown | 0.90 |
| mitochondrial_dysfunction | mediates | mechanism | 0.90 |
| neuroprotection | contributes_to | phenotype | 0.90 |
| glucose homeostasis | contributes_to | unknown | 0.90 |
| cholesterol homeostasis | contributes_to | unknown | 0.90 |
| neuropathic pain | protects_against | unknown | 0.90 |
| Parkinson's disease | involved_in | unknown | 0.90 |
| glioblastoma | associated_with | unknown | 0.85 |
| oxidative_stress | contributes_to | phenotype | 0.85 |
| therapy_resistance | contributes_to | unknown | 0.85 |
| cell survival | contributes_to | unknown | 0.85 |
| mitochondrial_dysfunction | contributes_to | mechanism | 0.85 |
| mitochondrial_dysfunction | associated_with | mechanism | 0.85 |
| ischemic stroke | involved_in | unknown | 0.85 |
| neurodegeneration | contributes_to | disease | 0.85 |
| neurodegeneration | associated_with | disease | 0.85 |
| nerve degeneration | associated_with | unknown | 0.85 |
| oxidative_stress | modulates | phenotype | 0.82 |
| ischemia/reperfusion injury | mediates | unknown | 0.80 |
| oxidative stress | modulates | mechanism | 0.80 |
| small fibre neuropathy | associated_with | unknown | 0.80 |
| mitochondrial_dysfunction | modulates | mechanism | 0.80 |
| neuronal survival | modulates | unknown | 0.80 |
| HK2 | associated_with | protein | 0.80 |
| neurodegeneration | inhibits | disease | 0.80 |
| aging-associated BBB breakdown | involved_in | unknown | 0.80 |
| alzheimers | involved_in | disease | 0.80 |
| cognitive functions | modulates | unknown | 0.79 |
| oxidative_stress | associated_with | phenotype | 0.75 |
| microglial_activation | modulates | mechanism | 0.75 |
| neuroinflammation | involved_in | mechanism | 0.75 |
| tumour_invasion | contributes_to | unknown | 0.75 |
| glymphatic_clearance | associated_with | mechanism | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| astrocytes | involved_in | cell_type | 0.95 |
| Mfn2 deletion | inhibits | unknown | 0.95 |
| MYO10 | mediates | unknown | 0.95 |
| melatonin | promotes | drug | 0.95 |
| Tak1 | mediates | unknown | 0.95 |
| Dmp1-expressing astrocytes | mediates | unknown | 0.95 |
| CD38 | involved_in | protein | 0.90 |
| aging | associated_with | unknown | 0.85 |
| astrocytes | activates | cell_type | 0.80 |
| oxidative_stress | inhibits | phenotype | 0.80 |
| HSP70 | involved_in | protein | 0.75 |
| APOE4 | modulates | protein | 0.72 |
| HSP70 | mediates | protein | 0.71 |
| mitochondrial DNA release | associated_with | mechanism | 0.70 |
| microglial_activation | associated_with | mechanism | 0.70 |
| TFAM | involved_in | protein | 0.70 |
| TFAM | associated_with | protein | 0.70 |
| TFEB | modulates | protein | 0.68 |
| glymphatic_clearance | associated_with | mechanism | 0.65 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Mitochondrial Transfer Pathway Enhancement | 0.695 | neurodegeneration | Astrocyte reactivity subtypes in neurode |
| CX43 hemichannel engineering enables size-selective mitochon | 0.686 | neurodegeneration | Mitochondrial transfer between astrocyte |
| GAP43-mediated tunneling nanotube stabilization enhances neu | 0.666 | neurodegeneration | Mitochondrial transfer between astrocyte |
| Optogenetic Control of Mitochondrial Transfer Networks | 0.476 | neurodegeneration | Mitochondrial transfer between neurons a |
| Astrocyte CD38-erk Mapk signaling controls mitochondrial tra | 0.000 | ALS and Alzheimer's disease | Mitochondrial transfer between neurons a |
Scientific analyses that reference this entity
cell biology | 2026-04-12 | 2 hypotheses Top: 0.724
neurodegeneration | 2026-04-11 | 0 hypotheses
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.559
neurodegeneration | 2026-04-01 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Cx43 knockdown effects on mitochondrial transfer | exploratory | osteoarthritis | 0.900 | 0.00 | human bone marrow-derived MSCs | proposed | N/A |
| Confocal imaging of MSC-chondrocyte interactions during mitochondrial | exploratory | osteoarthritis | 0.850 | 0.00 | human bone marrow-derived MSCs | proposed | N/A |
| Auditory nerve responses to combined optogenetic and electrical stimul | validation | sensorineural hearing loss/dea | 0.850 | 0.00 | transgenic mice expressing ChR | proposed | N/A |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Cytochrome Therapeutics | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| AAV-LRRK2 IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Gap Junction Dysfunction Validation in Parkinson's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| AAV-LRRK2 Gene Therapy IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson' | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Axonal Transport Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Enhancer AAVs for targeting spinal motor neurons and descending motor pathways i [PMID:40403722] | Emily Kussick, Nelson Johansen, Naz Task | Cell Reports | 2025 | 19 |
| Organelle-specific autophagy in inflammatory diseases: a potential therapeutic t [PMID:32048886] | Yao RQ, Ren C, Xia ZF, Yao YM | Autophagy | 2021 | 2 |
| Astrocytic Connexin43 in Alzheimer's disease: mechanisms, interaction with P2 re [PMID:41062060] | Xiong W, Su Y, Verkhratsky A, Yi C | Neuropharmacology | 2026 | 1 |
| Miro1: A potential target for treating neurological disorders. [PMID:40403957] | Zeng L, Yang J, Zhang C, Zhu J, Zhong S, | Neuroscience | 2025 | 1 |
| Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates co [PMID:40595567] | Su Y, Li H, Zhang W, Tao S, Wang Q, Zhan | Nat Commun | 2025 | 1 |
| Calcium-Associated Proteins in Neuroregeneration. [PMID:38397420] | Lisek M, Tomczak J, Boczek T, Zylinska L | Biomolecules | 2024 | 1 |
| Should it stay or should it go: gap junction protein GJA1/Cx43 conveys damaged l [PMID:39394955] | Domingues N, Ribeiro-Rodrigues T, Girão | Autophagy | 2024 | 1 |
| Connexin 43 regulates intercellular mitochondrial transfer from human mesenchyma [PMID:39390589] | Irwin RM, Thomas MA, Fahey MJ, Mayán MD, | Stem Cell Res Ther | 2024 | 1 |
| Mitochondria from osteolineage cells regulate myeloid cell-mediated bone resorpt [PMID:38877020] | Ding P, Gao C, Zhou J, Mei J, Li G, Liu | Nat Commun | 2024 | 1 |
| Selective inhibition of cannabinoid CB(1) receptor-evoked signalling by the inte [PMID:37689260] | Maroto IB, Moreno E, Costas-Insua C, Mer | Neuropharmacology | 2023 | 1 |
| lncRNA LOC100911717-targeting GAP43-mediated sympathetic remodeling after myocar [PMID:36684596] | Li P, Wang K, Yin J, Qi L, Hu H, Yang P, | Front Cardiovasc Med | 2022 | 1 |
| Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. [PMID:33803217] | Chang CH, Lin CH, Lane HY | Int J Mol Sci | 2021 | 1 |
| Astrocyte Networks as Therapeutic Targets in Glaucomatous Neurodegeneration. [PMID:34199470] | Boal AM, Risner ML, Cooper ML, Wareham L | Cells | 2021 | 1 |
| MIROs and DRP1 drive mitochondrial-derived vesicle biogenesis and promote qualit [PMID:34873283] | König T, Nolte H, Aaltonen MJ, Tatsuta T | Nat Cell Biol | 2021 | 1 |
| Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal ste [PMID:24431222] | Ahmad T, Mukherjee S, Pattnaik B, Kumar | EMBO J | 2014 | 1 |
| Nerve growth cone motility. [PMID:2139335] | Lankford K, Cypher C, Letourneau P | Curr Opin Cell Biol | 1990 | 1 |
| L-Carnitine and Acetyl-L-Carnitine in Drug Poisonings: A Systematic Review of Cl [PMID:41692009] | ["Rezaee H", "Abbasgholizadeh F"] | Journal of applied toxicology | 2026 | 0 |
| Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline [PMID:41618855] | ["Ying H", "Fan H", "Wang Y", "Jiang R", | Advanced science (Weinheim, Ba | 2026 | 0 |
| Prenatal lipopolysaccharide exposure programs cardiac fibrosis via dysregulating [PMID:41789580] | Wen Y, Yuan Y, Zhang H, Liu Y | Molecular medicine reports | 2026 | 0 |
| Astrocytes Protect Brain Metastatic Breast Cancer Cells From Chemotherapy Throug [PMID:41486609] | Yakati V, Rao SS | Biotechnol Bioeng | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
closed · Rounds: 4 · Score: 0.74 · 2026-04-12
closed · Rounds: 5 · Score: 0.81 · 2026-04-01
closed · Rounds: 4 · Score: 0.95 · 2026-04-01
Hypotheses and analyses mentioning mitochondrial_transfer in their description or question text
No additional research found